NASDAQ:SURF - Surface Oncology Stock Price, News, & Analysis

$3.32
-0.13 (-3.77 %)
(As of 06/14/2019 04:00 PM ET)
Today's Range
$3.29
Now: $3.32
$3.6250
50-Day Range
$3.48
MA: $4.08
$5.01
52-Week Range
$3.29
Now: $3.32
$18.18
Volume45,598 shs
Average Volume61,162 shs
Market Capitalization$92.43 million
P/E RatioN/A
Dividend YieldN/A
Beta3.03
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SURF
CUSIPN/A
CIKN/A
Phone617-714-4096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.42 million
Book Value$3.72 per share

Profitability

Net Income$-6,600,000.00
Net Margins-148.15%

Miscellaneous

Employees76
Market Cap$92.43 million
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.

Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

How were Surface Oncology's earnings last quarter?

Surface Oncology Inc (NASDAQ:SURF) issued its earnings results on Thursday, May, 9th. The company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.46) by $0.31. The company earned $14.43 million during the quarter, compared to the consensus estimate of $2.50 million. Surface Oncology had a negative return on equity of 38.97% and a negative net margin of 148.15%. View Surface Oncology's Earnings History.

When is Surface Oncology's next earnings date?

Surface Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Surface Oncology.

What price target have analysts set for SURF?

2 brokers have issued 12-month price targets for Surface Oncology's stock. Their predictions range from $23.00 to $23.00. On average, they expect Surface Oncology's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 592.8% from the stock's current price. View Analyst Price Targets for Surface Oncology.

What is the consensus analysts' recommendation for Surface Oncology?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Surface Oncology.

Has Surface Oncology been receiving favorable news coverage?

News stories about SURF stock have been trending somewhat positive recently, according to InfoTrie. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Surface Oncology earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the near term. View News Stories for Surface Oncology.

Who are some of Surface Oncology's key competitors?

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Anadarko Petroleum (APC), 22nd Century Group (XXII), AEterna Zentaris (AEZS), Allena Pharmaceuticals (ALNA), Green Plains (GPRE), Intuitive Surgical (ISRG), NVIDIA (NVDA), Boeing (BA), Berkshire Hathaway (BRK.B) and FedEx (FDX).

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the folowing people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 61)
  • Mr. J. Jeffrey Goater, CEO, Pres & Director (Age 44)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 56)
  • Dr. Robert W. Ross, Chief Medical Officer (Age 45)
  • Ms. Jessica Fees, Sr. VP of Fin. & Bus. Operations and Treasurer (Age 47)

When did Surface Oncology IPO?

(SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO.

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.84%), FIL Ltd (2.30%), Victory Capital Management Inc. (1.88%), Acadian Asset Management LLC (0.33%), Jacobs Levy Equity Management Inc. (0.33%) and Man Group plc (0.20%). Company insiders that own Surface Oncology stock include David S Grayzel and Lilly Ventures Fund I Llc. View Institutional Ownership Trends for Surface Oncology.

Which institutional investors are selling Surface Oncology stock?

SURF stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, Man Group plc, BlackRock Inc., Oxford Asset Management LLP, Alambic Investment Management L.P., Victory Capital Management Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Surface Oncology.

Which institutional investors are buying Surface Oncology stock?

SURF stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Jacobs Levy Equity Management Inc., Dimensional Fund Advisors LP, State of Wisconsin Investment Board, Spark Investment Management LLC, Rhumbline Advisers and California State Teachers Retirement System. Company insiders that have bought Surface Oncology stock in the last two years include David S Grayzel and Lilly Ventures Fund I Llc. View Insider Buying and Selling for Surface Oncology.

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $3.32.

How big of a company is Surface Oncology?

Surface Oncology has a market capitalization of $92.43 million and generates $59.42 million in revenue each year. The company earns $-6,600,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Surface Oncology employs 76 workers across the globe.View Additional Information About Surface Oncology.

What is Surface Oncology's official website?

The official website for Surface Oncology is http://www.surfaceoncology.com/.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]


MarketBeat Community Rating for Surface Oncology (NASDAQ SURF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  170
MarketBeat's community ratings are surveys of what our community members think about Surface Oncology and other stocks. Vote "Outperform" if you believe SURF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SURF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel